A bi-cruciate stabilized (BCS) guided-motion total knee arthroplasty (TKA) design was introduced to improve knee kinematics by more closely approximating those of a normal knee. Previous studies have shown a high incidence of complications with this implant type, which led to recent modifications of the design by the manufacturer. The current study was undertaken to assess whether the use of a guided-motion knee system with an extension-first surgical technique is associated with a similar rate of short-term adverse outcome as reported in literature. The secondary aim was to assess if there were any differences between the original and modified implant designs. This retrospective study enrolled 204 consecutive patients (204 knees) undergoing TKA for osteoarthritis of the knee, with the first 154 receiving cemented Journey BCS I implants and the remaining 51 receiving cemented Journey BCS II implants when these became available. At follow-up, patients were tested for the presence of iliotibial friction syndrome (ITB-F) and midflexion instability. Knee score and function score were taken preoperatively, at one year, and at final follow-up. Outcome data between the two implant types were compared using the Mann-Whitney test. No patients were lost to follow-up. Mean follow-up time for the cohort was 24.5 ± 7.8 months (range, 12 - 36 months). There were no cases of stiffness (flexion < 90°). Incidence of ITB-F syndrome was considered low: three (2.0%) knees in the BCS I group and two (3.9%) in the BCS II group (p = 0.367). Five (2.5%) knees presented with mild instability in midflexion, three (2.0%) in the BCS I group and two (3.9%) in the BCS II group (p = 0.367). One patient with a BCS I implant required reoperation for aseptic loosening 23 months postoperatively. At one-year follow-up, there were no significant differences in range of motion, knee score, or function score. When used in combination with an extension-first surgical technique, good early functional results with an acceptable rate of complications were obtained with both the original and the updated Journey BCS knee implant. Long-term follow-up studies are needed to confirm our findings.